Monthly Prescribing Reference

Trichomoniasis Treatment: Is it Reinfection or Resistant Infection?

Patient education and counseling are essential to properly treating trichomoniasis and determining recurrent or resistant infections. Health care providers should properly educate patients on proper ...
Healio

FDA approves supplemental NDA for secnidazole to treat trichomoniasis

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio The FDA this week approved a supplemental ...
EurekAlert!

It’s the most common STI you’ve never heard of. Will this newly developed drug provide the cure?

Researchers at Tulane University are leading a groundbreaking study to seek a more effective treatment for trichomoniasis, an infection that, despite being the most common curable sexually transmitted ...
Morningstar

FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis

SAN DIEGO, Aug. 19, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCID: EVFM) today announced that a newly-issued U.S. patent which covers SOLOSEC® (secnidazole) 2 g oral granules and one of its ...
Labroots

Current controversies in the Diagnosis and Treatment of Trichomonas vaginalis and Mycoplasma genitalium

Associate Professor of Medicine, Epidemiology, and Obstetrics & Gynecology in the Infectious Diseases Division at the University of Alabama at Birmingham ...
Monthly Prescribing Reference

Trichomoniasis Treatment: Is it Reinfection or Resistant Infection?

Credit: CDC/Joe Miller. Trichomoniasis is often asymptomatic and, if left untreated, can result in preterm delivery and other adverse pregnancy outcomes and an increased risk for pelvic inflammatory ...